Phaseline

Companies › Spur Therapeutics

Spur Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 1 Phase 3, 1 Phase 1; Metabolic and endocrine; next expected readout Jul 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
FLT201
AAV-mediated gene therapy delivering functional GBA gene
GBAPhase 3Gaucher Disease Type 1; Gaucher Disease, Type 1Jul 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07223944FLT201Phase 3Gaucher Disease Type 1Metabolic and endocrineJul 2028
NCT06545136FLT201Phase 1Gaucher Disease, Type 1Metabolic and endocrineMay 2029

Targets

GBA (1)

Companies with the same targets

Lingyi Biotech Prevail Therapeutics Azafaros Bial R&D Investments

Companies built like this

iECURE Yong Zhao, MD, PhD Grace Science Orchard Therapeutics BioLab Holdings

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.